534 related articles for article (PubMed ID: 28618999)
1. Biomarkers for Diagnosing and Staging of Fabry Disease.
Kramer J; Weidemann F
Curr Med Chem; 2018; 25(13):1530-1537. PubMed ID: 28618999
[TBL] [Abstract][Full Text] [Related]
2. Profiles of Globotriaosylsphingosine Analogs and Globotriaosylceramide Isoforms Accumulated in Body Fluids from Various Phenotypic Fabry Patients.
Shiga T; Tsukimura T; Kubota T; Togawa T; Sakuraba H
Intern Med; 2024 Jun; 63(11):1531-1537. PubMed ID: 37866916
[TBL] [Abstract][Full Text] [Related]
3. Fabry Disease Biomarkers: Analysis of Urinary Lyso-Gb3 and Seven Related Analogs Using Tandem Mass Spectrometry.
Lavoie P; Boutin M; Abaoui M; Auray-Blais C
Curr Protoc Hum Genet; 2016 Jul; 90():17.22.1-17.22.12. PubMed ID: 27367162
[TBL] [Abstract][Full Text] [Related]
4. Correlation of Lyso-Gb3 levels in dried blood spots and sera from patients with classic and Later-Onset Fabry disease.
Nowak A; Mechtler T; Kasper DC; Desnick RJ
Mol Genet Metab; 2017 Aug; 121(4):320-324. PubMed ID: 28663131
[TBL] [Abstract][Full Text] [Related]
5. Multiplex tandem mass spectrometry analysis of novel plasma lyso-Gb₃-related analogues in Fabry disease.
Boutin M; Auray-Blais C
Anal Chem; 2014 Apr; 86(7):3476-83. PubMed ID: 24634980
[TBL] [Abstract][Full Text] [Related]
6. Distributions of Globotriaosylceramide Isoforms, and Globotriaosylsphingosine and Its Analogues in an α-Galactosidase A Knockout Mouse, a Model of Fabry Disease.
Sueoka H; Aoki M; Tsukimura T; Togawa T; Sakuraba H
PLoS One; 2015; 10(12):e0144958. PubMed ID: 26661087
[TBL] [Abstract][Full Text] [Related]
7. Urinary biomarker investigation in children with Fabry disease using tandem mass spectrometry.
Auray-Blais C; Blais CM; Ramaswami U; Boutin M; Germain DP; Dyack S; Bodamer O; Pintos-Morell G; Clarke JT; Bichet DG; Warnock DG; Echevarria L; West ML; Lavoie P
Clin Chim Acta; 2015 Jan; 438():195-204. PubMed ID: 25149322
[TBL] [Abstract][Full Text] [Related]
8. Migalastat HCl reduces globotriaosylsphingosine (lyso-Gb3) in Fabry transgenic mice and in the plasma of Fabry patients.
Young-Gqamana B; Brignol N; Chang HH; Khanna R; Soska R; Fuller M; Sitaraman SA; Germain DP; Giugliani R; Hughes DA; Mehta A; Nicholls K; Boudes P; Lockhart DJ; Valenzano KJ; Benjamin ER
PLoS One; 2013; 8(3):e57631. PubMed ID: 23472096
[TBL] [Abstract][Full Text] [Related]
9. Tandem mass spectrometry multiplex analysis of methylated and non-methylated urinary Gb3 isoforms in Fabry disease patients.
Abaoui M; Boutin M; Lavoie P; Auray-Blais C
Clin Chim Acta; 2016 Jan; 452():191-8. PubMed ID: 26593248
[TBL] [Abstract][Full Text] [Related]
10. High-Risk Screening of Fabry Disease: Analysis of Fifteen Urinary Methylated and Non-Methylated Gb
Abaoui M; Boutin M; Lavoie P; Auray-Blais C
Curr Protoc Hum Genet; 2016 Oct; 91():17.24.1-17.24.11. PubMed ID: 27727434
[TBL] [Abstract][Full Text] [Related]
11. Multiplex analysis of novel urinary lyso-Gb3-related biomarkers for Fabry disease by tandem mass spectrometry.
Lavoie P; Boutin M; Auray-Blais C
Anal Chem; 2013 Feb; 85(3):1743-52. PubMed ID: 23248976
[TBL] [Abstract][Full Text] [Related]
12. Globotriaosylsphingosine (Lyso-Gb
Alharbi FJ; Baig S; Auray-Blais C; Boutin M; Ward DG; Wheeldon N; Steed R; Dawson C; Hughes D; Geberhiwot T
J Inherit Metab Dis; 2018 Mar; 41(2):239-247. PubMed ID: 29294190
[TBL] [Abstract][Full Text] [Related]
13. Globotriaosylsphingosine (lyso-Gb
Effraimidis G; Feldt-Rasmussen U; Rasmussen ÅK; Lavoie P; Abaoui M; Boutin M; Auray-Blais C
J Med Genet; 2021 Oct; 58(10):692-700. PubMed ID: 32963035
[TBL] [Abstract][Full Text] [Related]
14. Tandem Mass Spectrometry Quantitation of Lyso-Gb3 and Six Related Analogs in Plasma for Fabry Disease Patients.
Boutin M; Lavoie P; Abaoui M; Auray-Blais C
Curr Protoc Hum Genet; 2016 Jul; 90():17.23.1-17.23.9. PubMed ID: 27367163
[TBL] [Abstract][Full Text] [Related]
15. Variations in the GLA gene correlate with globotriaosylceramide and globotriaosylsphingosine analog levels in urine and plasma.
Ferreira S; Auray-Blais C; Boutin M; Lavoie P; Nunes JP; Martins E; Garman S; Oliveira JP
Clin Chim Acta; 2015 Jul; 447():96-104. PubMed ID: 26070511
[TBL] [Abstract][Full Text] [Related]
16. Pathogenesis and Molecular Mechanisms of Anderson-Fabry Disease and Possible New Molecular Addressed Therapeutic Strategies.
Tuttolomondo A; Simonetta I; Riolo R; Todaro F; Di Chiara T; Miceli S; Pinto A
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576250
[TBL] [Abstract][Full Text] [Related]
17. Nano-LC-MS/MS for Quantification of Lyso-Gb3 and Its Analogues Reveals a Useful Biomarker for Fabry Disease.
Sueoka H; Ichihara J; Tsukimura T; Togawa T; Sakuraba H
PLoS One; 2015; 10(5):e0127048. PubMed ID: 25965380
[TBL] [Abstract][Full Text] [Related]
18. A comprehensive testing algorithm for the diagnosis of Fabry disease in males and females.
Stiles AR; Zhang H; Dai J; McCaw P; Beasley J; Rehder C; Koeberl DD; McDonald M; Bali DS; Young SP
Mol Genet Metab; 2020 Jul; 130(3):209-214. PubMed ID: 32418857
[TBL] [Abstract][Full Text] [Related]
19. A simple method for quantification of plasma globotriaosylsphingosine: Utility for Fabry disease.
Talbot A; Nicholls K; Fletcher JM; Fuller M
Mol Genet Metab; 2017 Sep; 122(1-2):121-125. PubMed ID: 28847675
[TBL] [Abstract][Full Text] [Related]
20. Plasma globotriaosylsphingosine as a biomarker of Fabry disease.
Togawa T; Kodama T; Suzuki T; Sugawara K; Tsukimura T; Ohashi T; Ishige N; Suzuki K; Kitagawa T; Sakuraba H
Mol Genet Metab; 2010 Jul; 100(3):257-61. PubMed ID: 20409739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]